EUVIMEDEUVIMED entdecken
Multizentrische Studie

Association between response to enfortumab vedotin and peripheral neuropathy in urothelial carcinoma patients: a multicenter retrospective study

Nozomi Hayakawa, Eiji Kikuchi, Go Kaneko, Ryo Yamashita, Daiki Ikarashi, Yuki Endo, Kimitsugu Usui, Wataru Obara iD, Masafumi Oyama, Yukihiro Kondo

Japanese Journal of Clinical Oncology · 02.11.2024 · 54 (11) · 1194-1200

DOI: 10.1093/jjco/hyae082 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Japanese Journal of Clinical Oncology, online erschienen am 29.06.2024. Verfasst von Nozomi Hayakawa und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, St. Marianna University School of Medicine, Kanagawa, Kanagawa, Japan. Hauptthemen laut MEDLINE: Peripheral Nervous System Diseases. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 19 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Enfortumab vedotin (EV) was approved for patients with metastatic urothelial carcinoma (mUC) who progressed after anticancer therapy on September 2021 in Japan. The association between the occurrence of EV-related side effects and clinical outcome remains to be elucidated.

Methods

We identified 97 mUC patients treated with EV therapy at our five institutions from the date of approval to March 2023. The median follow-up period was 7.0 months. We retrospectively analyzed the efficacy and safety of EV.

Results

The median age of the patients was 71 years old, 39% had PS of 1 or more, and 56.7% had primary tumor in upper urinary tract. Overall response rate (ORR) to EV therapy, median progression-free survival (PFS), and overall survival (OS) were 43.3%, 7.52 months, and 12.78 months, respectively. Any grade of treatment-related skin disorder, dysgeusia, peripheral neuropathy, gastrointestinal disorder, and hyperglycemia occurred in 61 (62.9%), 36 (37.1%), 34 (35.1%), 29 (29.9%), and 18 (18.6%) patients, respectively. The patients with EV-associated peripheral neuropathy had significantly higher ORR (58.8% vs. 34.9%, P = .032) and longer median PFS (8.05 vs. 6.31 months, P = .017) and OS (not reached vs. 11.57 months, P = .008, respectively) than those without. The occurrence of peripheral neuropathy after EV treatment and the presence of peritoneal dissemination were factors independently associated with PFS (hazard ratio = 0.46, P = .008 and hazard raito = 3.83, P = .004, respectively) and OS (hazard ratio = 0.30, P = .005 and hazard raito = 4.53, P = .002, respectively).

Conclusions

The occurrence of EV-related peripheral neuropathy might be associated with the efficacy of EV therapy in mUC patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Peripheral Nervous System DiseasesHumansMaleAgedFemaleRetrospective StudiesMiddle AgedAged, 80 and overAntibodies, MonoclonalUrologic NeoplasmsProgression-Free SurvivalCarcinoma, Transitional Cell

Stichwörter der Autor:innen

enfortumab vedotinmulticenter studyperipheral neuropathyurothelial carcinoma

Substanzen

enfortumab vedotinAntibodies, Monoclonal

Autor:innen und Institutionen

  • Department of Urology, St. Marianna University School of Medicine, Kanagawa, Kanagawa, Japan.
  • Department of Uro-Oncology, Saitama Medical University International Medical Center, Saitama, Japan.
  • Division of Urology, Shizuoka Cancer Center, Suntougun, Shizuoka, Japan.
  • Department of Urology, Iwate Medical University School of Medicine, Iwate, Japan.
  • Department of Urology, Nippon Medical School, Tokyo, Japan.

ORCID-Profile: Wataru Obara

Zitieren

APA

Hayakawa, N., Kikuchi, E., Kaneko, G., Yamashita, R., Ikarashi, D., Endo, Y., Usui, K., Obara, W., Oyama, M., & Kondo, Y. (2024). Association between response to enfortumab vedotin and peripheral neuropathy in urothelial carcinoma patients: a multicenter retrospective study. Japanese Journal of Clinical Oncology, 54(11), 1194-1200. https://doi.org/10.1093/jjco/hyae082

Vancouver

Hayakawa N, Kikuchi E, Kaneko G, Yamashita R, Ikarashi D, Endo Y, et al. Association between response to enfortumab vedotin and peripheral neuropathy in urothelial carcinoma patients: a multicenter retrospective study. Japanese Journal of Clinical Oncology. 2024;54(11):1194-1200. doi:10.1093/jjco/hyae082

BibTeX
@article{Hayakawa2024,
  author = {Hayakawa, Nozomi and Kikuchi, Eiji and Kaneko, Go and Yamashita, Ryo and Ikarashi, Daiki and Endo, Yuki and Usui, Kimitsugu and Obara, Wataru and Oyama, Masafumi and Kondo, Yukihiro},
  title = {Association between response to enfortumab vedotin and peripheral neuropathy in urothelial carcinoma patients: a multicenter retrospective study},
  journal = {Japanese Journal of Clinical Oncology},
  year = {2024},
  volume = {54},
  number = {11},
  pages = {1194--1200},
  doi = {10.1093/jjco/hyae082}
}
Kostenlos starten →